Mark Andersen

Mark Andersen

Directeur Financier/CFO chez FIBROBIOLOGICS, INC.

53 ans
Health Technology
Commercial Services
Consumer Services

Profil

Mark Andersen is currently the Chief Financial Officer at FibroBiologics, Inc. He previously worked as the Investments Director-Pension Plan at Eli Lilly & Co. from 2004 to 2015, Vice President-Finance & Controller at MiMedx, Inc. from 2015 to 2016, Head-Controller at Lilly USA LLC, Auditor at Deloitte Development LLC from 1998 to 1999, and Auditor at KPMG US LLP from 1996 to 1998.
He also served as the Chief Financial Officer & VP-Administration at Indiana Biosciences Research Institute from 2016 to 2022.
Andersen received his undergraduate and graduate degrees from Southern Utah University and his MBA from Stephen M.
Ross School of Business.

Postes actifs de Mark Andersen

SociétésPosteDébut
FIBROBIOLOGICS, INC. Directeur Financier/CFO 01/06/2022
Tous les postes actifs de Mark Andersen

Anciens postes connus de Mark Andersen

SociétésPosteFin
Directeur Financier/CFO 01/05/2022
Directeur Financier/CFO 01/02/2016
ELI LILLY AND COMPANY Corporate Officer/Principal 01/08/2015
Comptroller/Controller/Auditor 01/01/1999
Comptroller/Controller/Auditor 01/01/1998
Voir l'expérience en détail de Mark Andersen

Formation de Mark Andersen

Southern Utah University Graduate Degree
Stephen M. Ross School of Business Masters Business Admin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Mark Andersen

Relations

100 +

Relations au 1er degré

9

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées2
FIBROBIOLOGICS, INC.

Health Technology

ELI LILLY AND COMPANY

Health Technology

Entreprise privées5

Commercial Services

Health Technology

Health Technology

Commercial Services

Commercial Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Mark Andersen